PhaseBio Pharmaceuticals Inc
OTC:PHASQ

Watchlist Manager
PhaseBio Pharmaceuticals Inc Logo
PhaseBio Pharmaceuticals Inc
OTC:PHASQ
Watchlist
Price: 0.0001 USD
Market Cap: 49.9 USD

Net Margin
PhaseBio Pharmaceuticals Inc

-1 210.2%
Current
-11 225%
Average
-6.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 210.2%
=
Net Income
-131.1m
/
Revenue
10.8m

Net Margin Across Competitors

No Stocks Found

PhaseBio Pharmaceuticals Inc
Glance View

Market Cap
49.9 USD
Industry
Biotechnology

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.

PHASQ Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 210.2%
=
Net Income
-131.1m
/
Revenue
10.8m
What is the Net Margin of PhaseBio Pharmaceuticals Inc?

Based on PhaseBio Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -1 210.2%.

Back to Top